For the quarter ending 2025-09-30, RGNX had -$20,756K decrease in cash & cash equivalents over the period. -$56,451K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Revenues-Operating Segments | 140,104 | - |
| Cost of license and royalty revenues-Operating Segments | 14,370 | - |
| Total research and development expense-Operating Segments | 168,688 | - |
| Total general and administrative expense-Operating Segments | 60,483 | - |
| Other segment items | 23,292 | - |
| Net loss | -61,941 | -64,788 |
| Stock-based compensation expense | 8,998 | 17,190 |
| Depreciation and amortization | 3,886 | 7,860 |
| Net accretion of discounts on marketable debt securities | 1,823 | 2,427 |
| Net realized gain on investments | 62 | - |
| Non-cash interest expense | 5,305 | 2,490 |
| Other non-cash adjustments | -48 | -12 |
| Accounts receivable | 6,310 | 790 |
| Prepaid expenses | 2,167 | 1,709 |
| Other current assets | -7 | 5,593 |
| Operating lease right-of-use assets | -1,683 | -3,306 |
| Other assets | 2,389 | -2,121 |
| Accounts payable | 694 | -1,117 |
| Accrued expenses and other current liabilities | 2,751 | -2,567 |
| Deferred revenue | -3,400 | 37,666 |
| Operating lease liabilities | -1,224 | -4,396 |
| Other liabilities | -16 | -2,971 |
| Net cash used in operating activities | -55,960 | -15,713 |
| Purchases of marketable debt securities | 39,521 | 230,298 |
| Maturities of marketable debt securities | 82,237 | 136,020 |
| Sales of equity securities | 62 | - |
| Purchases of property and equipment | 491 | 1,415 |
| Net cash provided by (used in) investing activities | 42,287 | -95,693 |
| Proceeds from exercise of stock options | 0 | 228 |
| Taxes paid related to net settlement of stock-based awards | 123 | 510 |
| Proceeds from issuance of common stock under employee stock purchase plan | 741 | 307 |
| Offering expenses related to at-the-market offering program | 75 | 259 |
| Proceeds from issuance of royalty bond and warrants, net of transaction costs | -33 | 144,526 |
| Repayments under royalty monetization liabilities, net of interest | 7,593 | 10,854 |
| Net cash provided by financing activities | -7,083 | 133,438 |
| Net increase in cash and cash equivalents and restricted cash | -20,756 | 22,032 |
| Cash and cash equivalents at beginning of period | 59,556 | - |
| Cash and cash equivalents at end of period | 60,832 | - |
REGENXBIO Inc. (RGNX)
REGENXBIO Inc. (RGNX)